Commitment to Quality
Adherence to Good Manufacturing Practices and Quality by Design principles ensures product integrity and regulatory compliance at every stage.
About us
Advancing healthcare with quality and innovation
Science. Quality. Trust. Three words that decide what we build, what we refuse, and how we behave when nobody is auditing.
Our mission
To develop and manufacture pharmaceuticals of the highest quality and lower the cost of healthcare for patients through smart investments in R&D and efficient processes.
Our company
A formulations company, headquartered in Hyderabad
Established in 2014, we started commercial operations in the U.S. market in 2018. Our unwavering commitment to excellence, compliance and operational efficiency has positioned us as a trusted partner for global pharmaceutical companies.
- Global presence: serving markets across the U.S., Europe and emerging economies
- Regulatory approvals: compliant with USFDA, WHO-GMP and other leading authorities, with ongoing filings in the UK and Europe
- Manufacturing excellence: oral solid dosage forms, specialty formulations and advanced drug delivery systems
Core values
Integrity, quality, affordability and innovation at the core of everything we do
Values you can audit, not just read.
Focus on Innovation
Graviti channels a significant share of revenue into advanced research, enabling next-generation therapies and high-impact pharmaceutical solutions.
Responsible Partners
Transparent, trustworthy and accountable relationships with customers and stakeholders, focused on long-term collaborations that drive mutual growth.
Culture of Value
By offering superior generics at reduced costs, we empower caregivers to deliver affordable, effective treatments without compromising quality.
Leadership
Empowering leadership and a strong workforce
Graviti sits at the intersection of Indian industry and Indian healthcare — and so does the team that runs it.
G. Ravender Rao
Chairman
Mr. G. Ravender Rao is a reputed industrialist and technocrat with over three decades of experience across engineering and healthcare. A graduate in Mechanical Engineering from REC Warangal, he started his first venture, Yashoda Vacuum Industries, in 1978 and later established Yashoda Special Metals in 1985 — both becoming leaders in their fields.
A great visionary, Mr. Rao joined hands with his brothers Dr. G. Surender Rao and Mr. Devender Rao to establish the Yashoda Group of Hospitals. He currently heads the Group, where his engineering discipline and entrepreneurial instinct built one of India's national players in healthcare services.
Dheeraj Gorukanti
Managing Director
Mr. Dheeraj Gorukanti brings varied expertise across the healthcare provider space, spanning operations, human resources and marketing. He serves on the Board of Graviti Pharmaceuticals as Managing Director.
As Chief Executive Officer of Yashoda Group, he built a system that delivers high-quality care while assuring sound fiscal operation and cost-effective services. Before Yashoda, he worked at Boston Consulting Group in Washington DC, serving clients in pharma, retail and financial services. He holds a Bachelors in Mechanical Engineering from IIT Madras and an MBA from Duke University's Fuqua School of Business.
Suguna Raman
Director
Suguna is a senior healthcare executive with extensive experience in business strategy and marketing, and a strong background in brand management, new product development and customer engagement.
She has led pioneering innovation and emerging technology programmes for leading healthcare organisations including Yashoda Healthcare and Graviti Pharmaceuticals, with a proven record in product launches, customer value propositions and large-scale delivery. She previously worked in international markets, including at Citibank in Singapore and New York. She completed her MBA at Duke University in 2007.
Our journey
From vision to impact
A decade of building trust, one milestone at a time.
2014
The founding intent
Launched with a vision to create a world-class pharmaceutical company, headquartered in Hyderabad.
2018
Into the regulated world
Entered the regulated U.S. market with USFDA-compliant formulations and commenced commercial operations.
2020
Building the backbone
Strengthened manufacturing and quality control infrastructure across the Hyderabad facility.
2023
Zero observations
Closed a regulatory inspection with zero 483 observations and expanded into cardiovascular, diabetes and specialty formulations.
2024
Zero-defect manufacturing
Driving automation, AI-based process enhancements and a zero-defect manufacturing agenda across the plant.
One facility in 2014. A global supply footprint today.
Growth story
From Hyderabad to the world
From a modest beginning to a team of 1000+, we have grown with purpose and passion.
Manufacturing Expansion
Increased production capacity with state-of-the-art facilities and planned expansions.
Regulatory Approvals
A strengthened presence in the world's most highly regulated markets.
Technology & Innovation
Advanced automation and AI-driven processes across manufacturing and quality.
Strategic Partnerships
Collaborations with leading global pharmaceutical companies.
Key achievementsSee how we hold quality
- Successful USFDA audits and global regulatory compliance
- Zero 483 observations in our most recent inspection
- Sustained efficiency improvements and zero-intervention operations